PDF
COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021
Organization: United States Centers for Disease Control (CDC)Published: 2022
"In preauthorization trials for Pfizer-BioNTech (BNT162b2) COVID-19 vaccine, vaccinated children aged 5–11 years reported mild to moderately severe local and systemic reactions; no serious vaccination-related events were noted.
After authorization of Pfizer-BioNTech COVID-19 vaccine for children aged 5–11 years during October 2021, and administration of approximately 8 million doses, local and systemic reactions after vaccination were commonly reported to VAERS and v-safe for vaccinated children aged 5–11 years. Serious adverse events were rarely reported.
Parents and guardians of children aged 5–11 years should be advised that local and systemic reactions are expected after vaccination with Pfizer-BioNTech COVID-19 vaccine and are more common after the second dose." - COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021
Additional Authors: John R. Su, Bicheng Zhang, Deborah Thompson, Tom T. Shimabukuro, David K. Shay
Product Type: Report
Category:
Vaccine Safety and Development,Vaccine Safety,Sub Topics: Vaccine Safety and Development,Adverse Events Following Immunization (AEFI),Vaccine Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Specific Populations,Children,School-aged Vaccine Safety and DevelopmentVaccine Safety
Sub Topics: Vaccine Safety and Development
Adverse Events Following Immunization (AEFI)
Vaccine Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Specific Populations
Children
School-aged
Link
AudioResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.